Endocrine Abstracts (2019) 68 OC3 | DOI: 10.1530/endoabs.68.OC3

Incidence and prevalence of neuroendocrine neoplasms reported in England from 2015 to 2017

Benjamin E White1, Catherine Bouvier2, Tracey Genus3, Brian Rous4, Rajaventhan Srirajaskanthan5, Kandiah Chandrakumaran1 & John K Ramage1


1Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK; 2Neuroendocrine Tumour Patient Foundation, Leamington Spa, UK; 3Public Health England, Birmingham, UK; 4Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 5King’s College Hospital NHS Foundation Trust, London, UK


Introduction: Previously published UK Cancer Registry data showed incidence of Neuroendocrine Neoplasms rising between 2001 and 2015. This was higher than had been thought (Genus et al.). We report more recent data with more accurate coding (ICD-O-3).

Aim: To analyse National Cancer Registration and Analysis Service (NCRAS) data on Neuroendocrine Neoplasias (NENs) in England including years 2015–2017.

Methods: Public Health England data for incidence and prevalence of NEN were analysed from NCRAS. This included a breakdown by age group, site, morphology and grade.

Results: During 2015–2017, 14 138 NENs were diagnosed in England; 7093 (50.17%) female. In 2016 NEN incidence in England was 9.37 per 100 000 which remained around the same in 2017, unlike previous years’ rises. Incidence increased in the 65–74 age group and decreased in 75 plus. In terms of sites, NEN incidence increased for most, except in Lung Neuroendocrine Tumours (NET), which levelled off after previous yearly rises. Breast and female reproductive organ sites incidence has decreased. Morphology data demonstrated ‘Neuroendocrine tumour NOS (not otherwise specified)’ reduced with increases in both ‘Carcinoid tumour’ and ‘Atypical carcinoid tumour’ incidence, possibly due to recoding. Data on Grade showed NEC G3 incidence decreased sharply, continuing a trend since 2011, with NET G1/G2 continuing to rise. The 23-year prevalence for NENs in England was 26 735 (using survival of 108 554 cases). Taking a mid-year population of 55 619 430, 2017 prevalence was 48 per 100 000.

Discussion: Age standardised incidence of NEN has for the first time risen above 9 per 100 000. Decreasing incidence in 75 plus but rising in 65–74 age group requires further analysis. Incidence of lung tumours reduced for the first time. Improved coding of data may have reduced non-specific ‘NOS’ numbers. NEC G3 incidence decreased whilst NEC G1/G2 increased. Prevalence is higher than many other cancers.

Article tools

My recent searches

No recent searches.